Analyst Research

Report Title Price
ValuEngine Detailed Valuation Report for BAYRY
Provider: ValuEngine, Inc.
$127.00
Buy
Bayer - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider: Finlabo SIM Spa
$58.00
Buy
Bayer AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Bayer AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Bayer AG Gets EU Approval For Xarelto In Lung Embolism-Reuters


Tuesday, 20 Nov 2012 02:40am EST 

Reuters reported that Bayer AG said its Xarelto blood-thinning pill won approval by the European Union (EU) for the treatment of dangerous blood clots of the lung, a condition known as pulmonary embolism. The Company also won the green light from the EU Commission for the pill's use in preventing recurrent deep vein thrombosis, another form of blood clotting. 

Latest Developments for Bayer AG

Latest Key Developments in Pharmaceuticals

Company Quote

Bayer AG
(BAYRY.PK)
108.7
-0.5 -0.46%
3:59pm EDT